VENLAFAXINE BESYLATE

LOE Approaching

venlafaxine

NDAORALTABLET, EXTENDED RELEASE
Approved
Jun 2022
Lifecycle
LOE Approaching
Competitive Pressure
15/100
Clinical Trials
20

Clinical Trials (5)

NCT03432221N/AUnknown

Switching From SSRI to Desvenlafaxine on Cognitive Functioning

Started Apr 2018
36 enrolled
Major Depressive Disorder
NCT02819921Phase 4Terminated

Desvenlafaxine for Treatment of Hot Flashes in Women With Breast Cancer Taking Tamoxifen

Started Nov 2017
59 enrolled
Hot FlashesBreast Neoplasms
NCT02200406Phase 4Completed

Desvenlafaxine in Opioid-Dependent Patients

Started Jul 2014
18 enrolled
DepressionOpioid DependenceMethadone Treatment
NCT01537068Phase 4Completed

Desvenlafaxine vs. Placebo Treatment of Chronic Depression

Started Feb 2012
59 enrolled
Dysthymic DisorderDysthymiaChronic Depressive Disorder
NCT01485887Phase 3Completed

Venlafaxine ER Long-Term Extension Study for Major Depressive Disorder (MDD)

Started Jan 2012
50 enrolled
Major Depressive Disorder

Loss of Exclusivity

LOE Date
May 16, 2028
26 months away
Patent Expiry
May 16, 2028

Patent Records (1)

Patent #ExpiryTypeUse Code
7776358
May 16, 2028
Product